Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Punjab Chemicals & Crop Protection Ltd

| Q2 and H1 FY26 Post Results Conference Call

NEUTRAL SENTIMENT

Report Source

⬤4th Nov 25

Summary : Punjab Chemicals reported steady Q2 and H1 FY26 growth, driven by exports and new products, while navigating market recovery and investing in future capacity.

Management Perspective positive : Management expressed pleasure with steady performance, confidence in strategic direction, and belief in market recovery. They are actively pursuing growth initiatives like new products and CAPEX, and expect to compensate domestic shortfalls with export sales.

Concall Report Analysis & Insights

Business Overview

  1. Q2 FY26 revenue grew 5.4% year-on-year to Rs. 255.2 crores, driven by domestic and export markets.
  2. H1 FY26 revenue increased 18.6% year-on-year to Rs. 574.7 crores.
  3. Q2 EBITDA grew 2.5% year-on-year to Rs. 26.2 crores, with margins at 10.3%.
  4. H1 EBITDA grew 13.1% year-on-year to Rs. 60.6 crores, with margins at 10.5%.
  5. Capacity utilization remains healthy across all divisions, with Derabassi at 77% and Lalru at 62%.

Future Growth Prospects

  1. Developing several new molecules in agro and specialty chemicals for commercialization in coming quarters.
  2. New manufacturing block CAPEX is progressing to meet rising demand and support new product pipeline.
  3. Evaluating a new site for medium to long-term growth, diversifying manufacturing base and enhancing supply resilience.
  4. Targeting 15%-20% year-on-year revenue growth and 16%-18% EBITDA margins in the long run.
  5. Five new products are expected to be commercialized in FY26, with two already accepted well.

Management Insights

  1. Industry shows signs of recovery with normalizing inventory levels and stabilizing pricing trends.
  2. Global chemical industry improved due to easing supply chain pressure and stable raw material costs.
  3. Company delivered steady performance, driven by consistent momentum in domestic and export markets.
  4. Focus on operational excellence, product quality, and cost management strengthens competitiveness.
  5. Committed to innovation, expanding chemistry portfolio, and capturing value in niche specialty chemicals.

Signs of Skepticism

  1. Management did not provide specific product-wise margin differences between own products and CDMO products, citing confidentiality.
  2. The exact long-term impact of US tariffs remains unclear, though currently negligible.

Risk Factors

  1. Q2 EBITDA margin hit by 1% due to heavy floods and sudden jump in fuel prices.
  2. Unseasonal rains in October impacted domestic demand for the current season.
  3. Long-term impact of tariffs on US exports is yet to become clear.
  4. Pricing remains stable at lower levels, with significant improvement not yet seen.

Good To Know

  1. Q2 FY26 PAT was Rs. 18.5 crores (7.3% margin), H1 FY26 PAT was Rs. 39.2 crores (6.8% margin).
  2. Domestic sales contributed Rs. 115 crores in Q2 and Rs. 313 crores in H1; exports Rs. 140 crores in Q2 and Rs. 262 crores in H1.
  3. New products contributed 16% to revenue in H1, up from 12% last year.
  4. Effective tax rate is 25.168%, with a one-time write-back of Rs. 2 crores from an ITAT order.
  5. Other income mainly from foreign exchange gains due to Rupee depreciation and Euro appreciation.

Key Drivers

  1. New molecules drive future growth.
  2. CAPEX expands production capacity.
  3. Export demand remains robust.
  4. Industry recovery improves pricing.

Key Analyst Discussions

Competitive Environment

  1. Export performance improved due to lower global inventories and healthy demand from Europe, US, Japan.
  2. Company maintains market share despite Chinese supplies being abundant, due to competitiveness.
  3. CDMO business contributes 55%-60% of total revenue, up from 45%-48% previously.

Market Trends & Consumer Behavior

  1. Overall industry pricing remains stable at lower end, with potential for improvement in a couple of quarters.
  2. Domestic demand impacted by unseasonal rains, but long-term trend remains healthy and growing.
  3. Export demand is healthy, compensating for any domestic sales shortfall.
  4. Market is slowly recovering, expecting normal conditions in 1-2 years, allowing better pricing.

Financial Highlights

  1. EBITDA margins for current year expected to be 11.5%-12.5%, excluding other income.
  2. Margin expansion levers include new product introduction, efficiency improvements, and backward integration.
  3. Total CAPEX for this year is about 35-40 crores for asset renewal and capacity expansion.
  4. New blocks will see 10-15 crores CAPEX this year, with majority in Q1-Q2 next year.
  5. Gross margins are expected to normalize to 38.5%-41% on a yearly basis.

Product Composition

  1. New products are expected to provide higher EBITDA margins and increase their share of revenue.
  2. Two of the five new products are for agro, one for pharma intermediate, and two for specialty chemicals.
  3. Three new products are for domestic market, two for export market.

Strategic Considerations

  1. Three new MOUs have a revenue potential of 125-150 crores once products mature.
  2. New Greenfield CAPEX of about 350 crores over three years, expected to conclude in next two quarters.
  3. Existing gross block can generate 350 crores revenue per quarter, maintaining current momentum.
  4. Brownfield block expected to be commercially available in Q3 of next year.